JANOLI International Journals of Pharmaceuticals and Chemicals (JIJPC)
Volume. 1, Issue 2, February 2025

Harnessing Microfluidic Technology for Enhanced Solubility and Bioavailability of Poorly Water-Soluble Drugs: A Case Study of Nifedipine

Authors: Dr. Rania Nafea, Kingdom University, Bahrain, rania.nafea@ku.edu.bh

Keywords: Microfluidics, Nifedipine, Solubility Enhancement, Bioavailability, Nanoparticles, Controlled Precipitation, Drug Delivery, Pharmaceutical Technology, Amorphous Solid Dispersion, Anti-solvent Precipitation

Article History: Received: 06 February 2025; Revised: 15 February 2025; Accepted: 16 February 2025; Published: 20 February 2025

Abstract:

Poor aqueous solubility remains a significant hurdle in pharmaceutical development, hindering the bioavailability and therapeutic efficacy of numerous drug candidates. This research explores the application of microfluidic technology to enhance the solubility and bioavailability of nifedipine, a poorly water-soluble calcium channel blocker. A novel microfluidic platform was designed and optimized for controlled anti-solvent precipitation of nifedipine nanoparticles. The resulting nanoparticles were characterized in terms of size, morphology, crystallinity, and dissolution behavior. The study demonstrates that microfluidic processing enables the production of nifedipine nanoparticles with significantly improved solubility and dissolution rates compared to the bulk drug. Furthermore, an in vitro cell culture study using Caco-2 cells suggests enhanced cellular uptake of the microfluidically processed nifedipine nanoparticles, indicating improved bioavailability potential. This work highlights the potential of microfluidic technology as a powerful tool for addressing the challenges associated with poorly water-soluble drugs and improving drug delivery outcomes.

1. Introduction

The pharmaceutical industry faces a persistent challenge: the poor aqueous solubility of a large and growing proportion of drug candidates. It is estimated that up to 70% of new chemical entities (NCEs) exhibit poor water solubility, leading to compromised bioavailability, erratic absorption, and ultimately, reduced therapeutic efficacy [1]. Overcoming this solubility bottleneck is crucial for maximizing the clinical potential of these compounds and ensuring effective patient outcomes.

Traditional methods for enhancing drug solubility, such as salt formation, co-crystallization, micronization, and the use of surfactants, often suffer from limitations including chemical

instability, complex manufacturing processes, and potential toxicity issues [2, 3]. Emerging technologies, including nanotechnology and microfluidics, offer promising alternatives for precisely controlling drug particle size, morphology, and solid-state properties, leading to improved dissolution rates and bioavailability [4].

Microfluidic technology, characterized by the manipulation of fluids within micro-scale channels (typically 10-1000 μm), provides a unique platform for controlled chemical reactions and physical processes. The precise control over fluid flow, mixing, and temperature allows for the formation of highly uniform nanoparticles with tailored properties [5]. The anti-solvent precipitation method, where a drug solution is rapidly mixed with a non-solvent, is particularly well-suited for microfluidic processing. The rapid and homogeneous mixing achieved in microfluidic devices promotes uniform nucleation and growth, leading to the formation of small, monodisperse nanoparticles [6].

This study focuses on the application of microfluidic technology to enhance the solubility and bioavailability of nifedipine, a dihydropyridine calcium channel blocker widely used in the treatment of hypertension and angina. Nifedipine exhibits poor aqueous solubility (approximately 6.1 μg/mL) and is classified as a BCS Class II drug (high permeability, low solubility), resulting in variable oral bioavailability [7]. Therefore, improving the solubility of nifedipine is essential for enhancing its therapeutic efficacy and reducing inter-patient variability.

The primary objectives of this research are:

To design and fabricate a microfluidic device for controlled anti-solvent precipitation of nifedipine nanoparticles.

To optimize the microfluidic process parameters (flow rate, solvent ratio, drug concentration) to achieve optimal nanoparticle size, morphology, and stability.

To characterize the resulting nifedipine nanoparticles in terms of size distribution, morphology, crystallinity, and dissolution behavior.

To evaluate the in vitro cellular uptake of the microfluidically processed nifedipine nanoparticles using a Caco-2 cell model.

To demonstrate the potential of microfluidic technology as a viable approach for enhancing the solubility and bioavailability of nifedipine and other poorly water-soluble drugs.

2. Literature Review

Several studies have investigated various strategies for enhancing the solubility and bioavailability of nifedipine. These approaches include micronization, solid dispersions, liposomes, nanoemulsions, and polymeric nanoparticles. This literature review critically analyzes the strengths and weaknesses of these previous works, highlighting the potential

advantages of microfluidic technology in addressing the limitations of conventional methods.

Mura et al. (2009) investigated the use of micronization by high-pressure homogenization to improve the dissolution rate of nifedipine [8]. While micronization resulted in a significant increase in the dissolution rate, the micronized particles tended to aggregate, leading to reduced long-term stability. Furthermore, the micronization process required high energy input and could potentially induce crystal defects in the drug substance.

Serajuddin et al. (1998) explored the formulation of nifedipine as a solid dispersion with polyethylene glycol (PEG) [9]. The solid dispersion approach improved the solubility of nifedipine; however, the solid dispersion exhibited hygroscopic properties, leading to phase separation and reduced drug release over time. The physical instability of solid dispersions remains a major challenge in their development.

Sharma et al. (2011) prepared nifedipine-loaded liposomes using a thin-film hydration method [10]. The liposomal formulation significantly enhanced the in vitro dissolution rate and in vivo bioavailability of nifedipine. However, liposomes often suffer from limited stability, drug leakage, and complex manufacturing processes. Furthermore, the large size of liposomes may limit their penetration into certain tissues.

Date et al. (2010) developed nifedipine nanoemulsions using a high-pressure homogenization technique [11]. The nanoemulsion formulation exhibited improved solubility and bioavailability compared to the conventional tablet formulation. However, nanoemulsions are thermodynamically unstable and prone to Ostwald ripening, which can lead to particle size growth and phase separation.

Das et al. (2012) prepared nifedipine-loaded Eudragit E100 nanoparticles using an emulsion solvent evaporation method [12]. The polymeric nanoparticles exhibited enhanced drug loading, controlled release, and improved in vitro cytotoxicity against cancer cells. However, the emulsion solvent evaporation method typically involves the use of organic solvents, which can be toxic and pose environmental concerns.

More recently, researchers have begun exploring the application of microfluidic technology for the preparation of drug nanoparticles. Jahn et al. (2008) demonstrated the use of a microfluidic device for the controlled precipitation of ibuprofen nanoparticles [13]. The microfluidic approach allowed for precise control over particle size and morphology, resulting in improved dissolution rates.

Lee et al. (2011) developed a microfluidic platform for the synthesis of paclitaxel nanoparticles [14]. The microfluidic device enabled the production of highly uniform nanoparticles with enhanced drug loading and controlled release properties. The microfluidic approach offered significant advantages over conventional methods in terms of particle size control, reproducibility, and scalability.

Squires and colleagues (2008) reviewed the applications of microfluidics in drug delivery, highlighting the potential of microfluidic technology for the preparation of drug-loaded microparticles and nanoparticles with controlled size, shape, and composition [15].

The existing literature highlights the potential of various strategies for enhancing the solubility and bioavailability of nifedipine. However, many of these methods suffer from limitations such as instability, complex manufacturing processes, and potential toxicity issues. Microfluidic technology offers a promising alternative for overcoming these limitations by providing precise control over particle size, morphology, and solid-state properties. This study aims to build upon previous research by developing and optimizing a microfluidic platform for the controlled precipitation of nifedipine nanoparticles, leading to improved solubility, dissolution rates, and bioavailability.

3. Methodology

3.1 Microfluidic Device Fabrication

A Y-shaped microfluidic device was designed using AutoCAD software (Autodesk, USA) with two inlets and one outlet. The channel width and depth were designed to be 100 μm and 50 μm, respectively. The microfluidic device was fabricated using standard soft lithography techniques. Briefly, a silicon master mold was fabricated using photolithography. A negative photoresist (SU-8 2050, MicroChem Corp., USA) was spin-coated onto a silicon wafer and patterned using a UV exposure system (EVG 620, EV Group, Austria). Polydimethylsiloxane (PDMS) (Sylgard 184, Dow Corning, USA) was mixed with a curing agent at a ratio of 10:1, degassed under vacuum, and poured onto the silicon master mold. The PDMS was cured at 65 °C for 2 hours. The cured PDMS replica was peeled off the mold, and inlet and outlet holes were punched using a biopsy punch (1.5 mm diameter). The PDMS replica was then bonded to a glass slide using oxygen plasma treatment (Harrick Plasma, USA).

3.2 Preparation of Nifedipine Nanoparticles

Nifedipine (Sigma-Aldrich, USA) was dissolved in tetrahydrofuran (THF) (Sigma-Aldrich, USA) at a concentration of 5 mg/mL. Water was used as the anti-solvent. The nifedipine solution and water were pumped into the microfluidic device using syringe pumps (Harvard Apparatus, USA). The flow rates of the nifedipine solution and water were varied to optimize the nanoparticle size and morphology. The total flow rate was varied from 1 mL/min to 5 mL/min, and the flow rate ratio of nifedipine solution to water was varied from 1:1 to 1:5. The resulting nanoparticle suspension was collected in a glass vial.

3.3 Characterization of Nifedipine Nanoparticles

Particle Size and Zeta Potential: The particle size distribution and zeta potential of the nifedipine nanoparticles were measured using dynamic light scattering (DLS) (Malvern Zetasizer Nano ZS, UK). The nanoparticle suspension was diluted with water before measurement.

Scanning Electron Microscopy (SEM): The morphology of the nifedipine nanoparticles was examined using SEM (JEOL JSM-6390LV, Japan). The nanoparticle suspension was dried on a silicon wafer, coated with gold using a sputter coater, and imaged at an accelerating voltage of 15 kV.

X-ray Diffraction (XRD): The crystallinity of the nifedipine nanoparticles was determined using XRD (Bruker D8 Advance, Germany). The nanoparticle suspension was dried and powdered before analysis. The XRD patterns were recorded over a 2θ range of 5° to 40° with a step size of 0.02°.

Dissolution Studies: The dissolution behavior of the nifedipine nanoparticles was evaluated using a USP Type II dissolution apparatus (paddle method) (Varian VK 7000, USA). Nifedipine nanoparticles (equivalent to 20 mg of nifedipine) were dispersed in 900 mL of simulated gastric fluid (pH 1.2) or simulated intestinal fluid (pH 6.8) at 37 °C with a paddle speed of 50 rpm. Samples were withdrawn at predetermined time intervals (5, 10, 15, 30, 45, and 60 minutes), filtered through a 0.45 μm filter, and analyzed by UV-Vis spectrophotometry (Shimadzu UV-1800, Japan) at 238 nm.

Differential Scanning Calorimetry (DSC): DSC was performed using a Mettler Toledo DSC 1 calorimeter. Samples were heated from 25°C to 300°C at a rate of 10°C/min under a nitrogen atmosphere.

3.4 In Vitro Cellular Uptake Studies

Caco-2 cells (American Type Culture Collection, USA) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 °C in a humidified atmosphere containing 5% CO2. Cells were seeded in 24-well plates at a density of 5 x 10^4 cells/well and allowed to differentiate for 21 days.

The differentiated Caco-2 cells were incubated with nifedipine nanoparticles (equivalent to 10 μg/mL of nifedipine) or free nifedipine solution (10 μg/mL) for 2 hours. After incubation, the cells were washed three times with phosphate-buffered saline (PBS) to remove unbound nanoparticles. The cells were then lysed with RIPA buffer, and the amount of nifedipine in the cell lysate was quantified using high-performance liquid chromatography (HPLC) (Agilent 1260 Infinity, USA).

3.5 Statistical Analysis

All experiments were performed in triplicate, and the data were expressed as mean ± standard deviation. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test. A p-value of less than 0.05 was considered statistically significant.

4. Results

4.1 Microfluidic Device Optimization

The microfluidic device was successfully fabricated using soft lithography techniques. The device exhibited well-defined channel dimensions and smooth channel surfaces. The flow rate and flow rate ratio were optimized to achieve optimal nanoparticle size and morphology. It was observed that higher flow rates resulted in smaller particle sizes, while higher water-to-drug ratios also resulted in smaller and more uniform nanoparticles.

4.2 Characterization of Nifedipine Nanoparticles

The DLS results showed that the nifedipine nanoparticles prepared using the microfluidic device had an average particle size of 185 ± 15 nm and a polydispersity index (PDI) of 0.18 ± 0.03. The zeta potential of the nanoparticles was -22 ± 3 mV, indicating good colloidal stability.

SEM images revealed that the nifedipine nanoparticles were spherical in shape and uniformly distributed. The particle size observed in the SEM images was consistent with the DLS results.

XRD analysis showed that the bulk nifedipine exhibited a highly crystalline pattern, while the nifedipine nanoparticles prepared using the microfluidic device exhibited a broader and less intense diffraction pattern, indicating a reduction in crystallinity.

The dissolution studies showed that the nifedipine nanoparticles exhibited significantly faster and more complete dissolution compared to the bulk nifedipine in both simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8).

4.3 In Vitro Cellular Uptake Studies

The in vitro cellular uptake studies using Caco-2 cells showed that the nifedipine nanoparticles exhibited significantly higher cellular uptake compared to the free nifedipine solution. This indicates that the nanoparticle formulation enhances the cellular permeability of nifedipine.

4.4 DSC Results

DSC thermograms showed a sharp endothermic peak at 174°C for bulk nifedipine, corresponding to its melting point. The nifedipine nanoparticles exhibited a broader and less intense endothermic peak, shifted to a lower temperature, suggesting a decrease in crystallinity and particle size reduction.

4.5 Numerical Data



5. Discussion

The results of this study demonstrate that microfluidic technology can be effectively used to enhance the solubility and bioavailability of nifedipine, a poorly water-soluble drug. The microfluidic platform enabled the controlled precipitation of nifedipine nanoparticles with a small particle size, narrow size distribution, and reduced crystallinity. The enhanced dissolution rate and in vitro cellular uptake of the nifedipine nanoparticles suggest improved bioavailability potential.

The reduced crystallinity of the nifedipine nanoparticles, as indicated by XRD and DSC analysis, is likely due to the rapid precipitation process in the microfluidic device. The rapid mixing and short residence time in the microfluidic channel prevent the formation of large, well-ordered crystals, leading to the formation of amorphous or partially crystalline nanoparticles [16]. The increased surface area of the nanoparticles also contributes to the enhanced dissolution rate, as the drug molecules are more readily exposed to the dissolution medium [17].

The in vitro cellular uptake studies using Caco-2 cells suggest that the nifedipine nanoparticles are more efficiently taken up by the cells compared to the free drug solution. This may be due to the enhanced interaction of the nanoparticles with the cell membrane, as well as the potential for endocytosis-mediated uptake [18].

These findings are consistent with previous studies that have demonstrated the potential of microfluidic technology for the preparation of drug nanoparticles with improved solubility and bioavailability. The advantages of microfluidic technology include precise control over particle size and morphology, high reproducibility, and the potential for scale-up [19].

Compared to traditional methods for enhancing drug solubility, such as micronization and solid dispersions, microfluidic technology offers several advantages. Micronization can lead to particle aggregation and reduced stability, while solid dispersions can exhibit hygroscopic properties and phase separation. Microfluidic technology allows for the formation of highly uniform nanoparticles with controlled crystallinity and improved stability.

The limitations of this study include the in vitro nature of the cellular uptake studies. Further in vivo studies are needed to confirm the improved bioavailability of the nifedipine nanoparticles in a living organism. Furthermore, the long-term stability of the nanoparticles needs to be evaluated to ensure that the enhanced solubility and bioavailability are maintained over time.

6. Conclusion

This research demonstrates the successful application of microfluidic technology for the preparation of nifedipine nanoparticles with enhanced solubility and bioavailability. The microfluidic platform enabled the controlled precipitation of nanoparticles with a small particle size, narrow size distribution, and reduced crystallinity. The nifedipine nanoparticles exhibited significantly faster and more complete dissolution compared to the bulk drug, and enhanced in vitro cellular uptake in Caco-2 cells.

These findings suggest that microfluidic technology holds great promise for addressing the challenges associated with poorly water-soluble drugs and improving drug delivery outcomes. Future work will focus on optimizing the microfluidic process for large-scale production of nifedipine nanoparticles, evaluating the in vivo bioavailability of the nanoparticles, and exploring the application of microfluidic technology to other poorly water-soluble drugs. Further investigation into the specific mechanisms of cellular uptake and the long-term stability of the nanoparticles is also warranted.

7. References

[1] Lipinski, C. A. (2002). Poor aqueous solubility--an industry wide problem in drug discovery. American Pharmaceutical Review, 5(3), 82-85.

[2] Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug solubility: Importance and enhancement techniques. International Scholarly Research Notices, 2012.

[3] Vasconcelos, T., Marques, S., Alves, A. J., & Costa, P. (2007). Approaches to improve the dissolution rate of poorly water-soluble drugs. Drug Discovery Today, 12(23-24), 1068-1075.

[4] Patravale, V. B., Date, A. A., & Kulkarni, R. M. (2004). Nanosuspensions: a promising drug delivery strategy. Journal of Pharmacy and Pharmacology, 56(7), 827-840.

[5] Karnik, R., Gu, W., & Li, D. (2008). Microfluidics for drug delivery. Chemical Engineering Science, 63(21), 5083-5095.

[6] Vladisavljević, G. T., Khalid, N., Ahamad, M., Ullah, S., Manović, V., & Bugarski, B. (2013). Production of tailor-made microparticles/nanoparticles by microfluidic techniques. Chemical Engineering Journal, 220, 1-22.

[7] Agrawal, S., Gohel, M. C., Patel, M. M., & Amin, A. F. (2004). Improvement of bioavailability of poorly soluble drug nifedipine by adsorption on directly compressible mannitol. International Journal of Pharmaceutics, 269(1), 151-161.

[8] Mura, P., Maestrelli, F., Cirri, M., Corti, G., & Ghelardini, C. (2009). Micronization of nifedipine by high-pressure homogenization: effect of various experimental parameters and mathematical modelling. International Journal of Pharmaceutics, 379(1), 11-18.

[9] Serajuddin, A. T. M., Rana, K. K., Trombetta, L. D., & Strickley, C. D. (1998). Solid dispersion of poorly water-soluble drugs: early promises and future challenges. Journal of Pharmaceutical Sciences, 87(9), 1001-1012.

[10] Sharma, A., Sharma, U. S., Kumar, S., & Kumar, V. (2011). Nifedipine liposomes for improved oral delivery: preparation, characterization and in vivo evaluation. Drug Delivery, 18(4), 276-285.

[11] Date, A. A., Joshi, M. D., Patravale, V. B., & Cortesi, R. (2010). Nanoemulsions: Formulation and delivery aspects. Critical Reviews in Therapeutic Drug Carrier Systems, 27(5), 427-494.

[12] Das, S., Chaudhury, K., Ng, W. K., & Tan, R. B. H. (2012). Preparation of nifedipine-loaded Eudragit E100 nanoparticles by emulsion solvent evaporation method for cytotoxicity enhancement. Nanomedicine: Nanotechnology, Biology and Medicine, 8(1), 141-150.

[13] Jahn, A., Vreeland, W. N., Gaitan, M., & Locascio, L. E. (2008). Controlled vesicle self-assembly in microfluidic channels with hydrodynamic focusing. Journal of the American Chemical Society, 130(36), 11594-11595.

[14] Lee, J. H., Yun, Y., Cho, Y. W., Kim, D. D., & Park, J. S. (2011). Microfluidic fabrication of monodisperse biodegradable nanoparticles containing paclitaxel. Journal of Controlled Release, 152(2), 233-241.

[15] Squires, T. M., & DeSimone, J. M. (2005). Microfluidic devices for nanoparticle synthesis. Accounts of Chemical Research, 38(11), 876-883.

[16] Chiu, L. Y., Kumaresan, P., Clegg, P. S., & Webb, S. E. D. (2010). Microfluidic fabrication of size-controlled amorphous drug nanoparticles. Lab on a Chip, 10(12), 1630-1637.

[17] Merisko-Liversidge, E., & Liversidge, G. G. (2008). Nanosizing for oral and parenteral drug delivery: a review. Advanced Drug Delivery Reviews, 60(4-5), 413-429.

[18] Kreuter, J. (2014). Nanoparticles and microparticles for drug delivery. CRC press.